BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 34254291)

  • 1. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.
    Català A; Muñoz-Santos C; Galván-Casas C; Roncero Riesco M; Revilla Nebreda D; Solá-Truyols A; Giavedoni P; Llamas-Velasco M; González-Cruz C; Cubiró X; Ruíz-Villaverde R; Gómez-Armayones S; Gil Mateo MP; Pesqué D; Marcantonio O; Fernández-Nieto D; Romaní J; Iglesias Pena N; Carnero Gonzalez L; Tercedor-Sanchez J; Carretero G; Masat-Ticó T; Rodríguez-Jiménez P; Gimenez-Arnau AM; Utrera-Busquets M; Vargas Laguna E; Angulo Menéndez AG; San Juan Lasser E; Iglesias-Sancho M; Alonso Naranjo L; Hiltun I; Cutillas Marco E; Polimon Olabarrieta I; Marinero Escobedo S; García-Navarro X; Calderón Gutiérrez MJ; Baeza-Hernández G; Bou Camps L; Toledo-Pastrana T; Guilabert A
    Br J Dermatol; 2022 Jan; 186(1):142-152. PubMed ID: 34254291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study.
    Cebeci Kahraman F; Savaş Erdoğan S; Aktaş ND; Albayrak H; Türkmen D; Borlu M; Arıca DA; Demirbaş A; Akbayrak A; Polat Ekinci A; Gökçek GE; Çelik HA; Taşolar MK; An İ; Temiz SA; Hazinedar E; Ayhan E; Hızlı P; Solak EÖ; Kılıç A; Yılmaz E
    J Cosmet Dermatol; 2022 Sep; 21(9):3692-3703. PubMed ID: 35780311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant).
    Sandhu S; Bhatnagar A; Kumar H; Dixit PK; Paliwal G; Suhag DK; Patil C; Mitra D
    Dermatol Ther; 2021 Nov; 34(6):e15141. PubMed ID: 34546608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-SARS-CoV-2 IgA and IgG in human milk after vaccination is dependent on vaccine type and previous SARS-CoV-2 exposure: a longitudinal study.
    Selma-Royo M; Bäuerl C; Mena-Tudela D; Aguilar-Camprubí L; Pérez-Cano FJ; Parra-Llorca A; Lerin C; Martínez-Costa C; Collado MC
    Genome Med; 2022 Apr; 14(1):42. PubMed ID: 35449030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
    McMahon DE; Amerson E; Rosenbach M; Lipoff JB; Moustafa D; Tyagi A; Desai SR; French LE; Lim HW; Thiers BH; Hruza GJ; Blumenthal KG; Fox LP; Freeman EE
    J Am Acad Dermatol; 2021 Jul; 85(1):46-55. PubMed ID: 33838206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.
    Singh RB; Parmar UPS; Ichhpujani P; Jeng BH; Jhanji V
    Cornea; 2023 Jun; 42(6):731-738. PubMed ID: 36706232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
    Krzywicka K; Heldner MR; Sánchez van Kammen M; van Haaps T; Hiltunen S; Silvis SM; Levi M; Kremer Hovinga JA; Jood K; Lindgren E; Tatlisumak T; Putaala J; Aguiar de Sousa D; Middeldorp S; Arnold M; Coutinho JM; Ferro JM
    Eur J Neurol; 2021 Nov; 28(11):3656-3662. PubMed ID: 34293217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.
    Vokó Z; Kiss Z; Surján G; Surján O; Barcza Z; Pályi B; Formanek-Balku E; Molnár GA; Herczeg R; Gyenesei A; Miseta A; Kollár L; Wittmann I; Müller C; Kásler M
    Clin Microbiol Infect; 2022 Mar; 28(3):398-404. PubMed ID: 34838783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant).
    Job AM; Sudhamani B; Mohan M; Mohanasundaram SN
    Indian J Public Health; 2022; 66(1):83-85. PubMed ID: 35381724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2.
    Sprute R; Schumacher S; Pauls M; Pauls W; Cornely OA
    Drugs R D; 2021 Dec; 21(4):371-374. PubMed ID: 34351606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between SARS-CoV-2 vaccination and healthcare contacts for menstrual disturbance and bleeding in women before and after menopause: nationwide, register based cohort study.
    Ljung R; Xu Y; Sundström A; Leach S; Hallberg E; Bygdell M; Larsson M; Arthurson V; Gisslén M; Gedeborg R; Nyberg F
    BMJ; 2023 May; 381():e074778. PubMed ID: 37137493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Milk Antibody Response After Combining Two Different COVID-19 Vaccines: Mix-and-Match.
    Mulleners SJ; Juncker HG; van Gils MJ; van Goudoever JB; van Keulen BJ
    J Hum Lact; 2022 Aug; 38(3):401-406. PubMed ID: 35726498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.
    Falotico JM; Desai AD; Shah A; Ricardo JW; Lipner SR
    Am J Clin Dermatol; 2022 Sep; 23(5):729-737. PubMed ID: 35931925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
    Tompkins LK; Baggs J; Myers TR; Gee JM; Marquez PL; Kennedy SB; Peake D; Dua D; Hause AM; Strid P; Abara W; Rossetti R; Shimabukuro TT; Shay DK
    Vaccine; 2022 Dec; 40(52):7653-7659. PubMed ID: 36372665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.